Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global GABA Receptor Agonist Drug Industry: Supply and Demand, Markets and Prices 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global GABA Receptor Agonist Drug Market Status and Forecast (2016-2027)
      • 1.3.2 Global GABA Receptor Agonist Drug Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global GABA Receptor Agonist Drug Supply by Company

    • 2.1 Global GABA Receptor Agonist Drug Sales Volume by Company
    • 2.2 Global GABA Receptor Agonist Drug Sales Value by Company
    • 2.3 Global GABA Receptor Agonist Drug Price by Company
    • 2.4 GABA Receptor Agonist Drug Production Location and Sales Area of Main Manufacturers
    • 2.5 Trend of Concentration Rate

    3 Global and Regional GABA Receptor Agonist Drug Market Status by Category

    • 3.1 GABA Receptor Agonist Drug Category Introduction
      • 3.1.1 Bamaluzole
      • 3.1.2 Phenibut
      • 3.1.3 Baclofen
      • 3.1.4 Gaboxadol
      • 3.1.5 Klonopin (clonazepam)
      • 3.1.6 Tiagbine
    • 3.2 Global GABA Receptor Agonist Drug Market by Category
      • 3.2.1 Global GABA Receptor Agonist Drug Sales Volume by Category (2016-2021)
      • 3.2.2 Global GABA Receptor Agonist Drug Sales Value by Category (2016-2021)
      • 3.2.3 Global GABA Receptor Agonist Drug Price by Category (2016-2021)
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional GABA Receptor Agonist Drug Market Status by End User/Segment

    • 4.1 GABA Receptor Agonist Drug Segment by End User/Segment
      • 4.1.1 Attention Deficit Hyperactivity Disorder (ADHD)
      • 4.1.2 Psychiatric Disorders and Depression
      • 4.1.3 Alzheimer
      • 4.1.4 Epilepsy and Seizure
      • 4.1.5 Anxiety and Sleep Disorders
      • 4.1.6 Obesity and Alcoholism
    • 4.2 Global GABA Receptor Agonist Drug Market by End User/Segment
      • 4.2.1 Global GABA Receptor Agonist Drug Sales Volume by End User/Segment (2016-2021)
      • 4.2.2 Global GABA Receptor Agonist Drug Sales Value by End User/Segment (2016-2021)
      • 4.2.3 Global GABA Receptor Agonist Drug Price by End User/Segment (2016-2021)
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global GABA Receptor Agonist Drug Market Status by Region

    • 5.1 Global GABA Receptor Agonist Drug Market by Region
      • 5.1.1 Global GABA Receptor Agonist Drug Sales Volume by Region
      • 5.1.2 Global GABA Receptor Agonist Drug Sales Value by Region
    • 5.2 North America GABA Receptor Agonist Drug Market Status
    • 5.3 Europe GABA Receptor Agonist Drug Market Status
    • 5.4 Asia Pacific GABA Receptor Agonist Drug Market Status
    • 5.5 Central & South America GABA Receptor Agonist Drug Market Status
    • 5.6 Middle East & Africa GABA Receptor Agonist Drug Market Status

    6 North America GABA Receptor Agonist Drug Market Status

    • 6.1 North America GABA Receptor Agonist Drug Market by Country
      • 6.1.1 North America GABA Receptor Agonist Drug Sales Volume by Country (2016-2021)
      • 6.1.2 North America GABA Receptor Agonist Drug Sales Value by Country (2016-2021)
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe GABA Receptor Agonist Drug Market Status

    • 7.1 Europe GABA Receptor Agonist Drug Market by Country
      • 7.1.1 Europe GABA Receptor Agonist Drug Sales Volume by Country (2016-2021)
      • 7.1.2 Europe GABA Receptor Agonist Drug Sales Value by Country (2016-2021)
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific GABA Receptor Agonist Drug Market Status

    • 8.1 Asia Pacific GABA Receptor Agonist Drug Market by Country
      • 8.1.1 Asia Pacific GABA Receptor Agonist Drug Sales Volume by Country (2016-2021)
      • 8.1.2 Asia Pacific GABA Receptor Agonist Drug Sales Value by Country (2016-2021)
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America GABA Receptor Agonist Drug Market Status

    • 9.1 Central & South America GABA Receptor Agonist Drug Market by Country
      • 9.1.1 Central & South America GABA Receptor Agonist Drug Sales Volume by Country (2016-2021)
      • 9.1.2 Central & South America GABA Receptor Agonist Drug Sales Value by Country (2016-2021)
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa GABA Receptor Agonist Drug Market Status

    • 10.1 Middle East & Africa GABA Receptor Agonist Drug Market by Country
      • 10.1.1 Middle East & Africa GABA Receptor Agonist Drug Sales Volume by Country (2016-2021)
      • 10.1.2 Middle East & Africa GABA Receptor Agonist Drug Sales Value by Country (2016-2021)
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Supply Chain and Manufacturing Cost Analysis

    • 11.1 Supply Chain Analysis
    • 11.2 Production Process Chart Analysis
    • 11.3 Raw Materials and Key Suppliers Analysis
      • 11.3.1 Raw Materials Introduction
      • 11.3.2 Raw Materials Key Suppliers List
    • 11.4 GABA Receptor Agonist Drug Manufacturing Cost Analysis
    • 11.5 GABA Receptor Agonist Drug Sales Channel and Distributors Analysis
      • 11.5.1 GABA Receptor Agonist Drug Sales Channel
      • 11.5.2 GABA Receptor Agonist Drug Distributors
    • 11.6 GABA Receptor Agonist Drug Downstream Major Buyers

    12 Global GABA Receptor Agonist Drug Market Forecast by Category and by End User/Segment

    • 12.1 Global GABA Receptor Agonist Drug Sales Volume and Sales Value Forecast (2022-2027)
    • 12.2 Global GABA Receptor Agonist Drug Forecast by Category
      • 12.2.1 Global GABA Receptor Agonist Drug Sales Volume Forecast by Category
      • 12.2.2 Global GABA Receptor Agonist Drug Sales Value Forecast by Category
      • 12.2.3 Global GABA Receptor Agonist Drug Price Forecast by Category
    • 12.3 Global GABA Receptor Agonist Drug Forecast by End User/Segment
      • 12.3.1 Global GABA Receptor Agonist Drug Sales Volume Forecast by End User/Segment
      • 12.3.2 Global GABA Receptor Agonist Drug Sales Value Forecast by End User/Segment
      • 12.3.3 Global GABA Receptor Agonist Drug Price Forecast by End User/Segment

    13 Global GABA Receptor Agonist Drug Market Forecast by Region/Country

    • 13.1 Global GABA Receptor Agonist Drug Market Forecast by Region (2022-2027)
      • 13.1.1 Global GABA Receptor Agonist Drug Sales Volume Forecast by Region (2022-2027)
      • 13.1.2 Global GABA Receptor Agonist Drug Sales Value Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 XenoPort
      • 14.1.1 Company Information
      • 14.1.2 GABA Receptor Agonist Drug Product Introduction
      • 14.1.3 XenoPort GABA Receptor Agonist Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 VIVUS
      • 14.2.1 Company Information
      • 14.2.2 GABA Receptor Agonist Drug Product Introduction
      • 14.2.3 VIVUS GABA Receptor Agonist Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 sanofi-aventis
      • 14.3.1 Company Information
      • 14.3.2 GABA Receptor Agonist Drug Product Introduction
      • 14.3.3 sanofi-aventis GABA Receptor Agonist Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Pfizer
      • 14.4.1 Company Information
      • 14.4.2 GABA Receptor Agonist Drug Product Introduction
      • 14.4.3 Pfizer GABA Receptor Agonist Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 OVATION Pharmaceuticals
      • 14.5.1 Company Information
      • 14.5.2 GABA Receptor Agonist Drug Product Introduction
      • 14.5.3 OVATION Pharmaceuticals GABA Receptor Agonist Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Osmotica Pharmaceutical
      • 14.6.1 Company Information
      • 14.6.2 GABA Receptor Agonist Drug Product Introduction
      • 14.6.3 Osmotica Pharmaceutical GABA Receptor Agonist Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 Novartis
      • 14.7.1 Company Information
      • 14.7.2 GABA Receptor Agonist Drug Product Introduction
      • 14.7.3 Novartis GABA Receptor Agonist Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 NovaDel Pharma
      • 14.8.1 Company Information
      • 14.8.2 GABA Receptor Agonist Drug Product Introduction
      • 14.8.3 NovaDel Pharma GABA Receptor Agonist Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 H.LundBeck, Merck and Co
      • 14.9.1 Company Information
      • 14.9.2 GABA Receptor Agonist Drug Product Introduction
      • 14.9.3 H.LundBeck, Merck and Co GABA Receptor Agonist Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.9.4 SWOT Analysis
    • 14.10 GlaxoSmithKline
      • 14.10.1 Company Information
      • 14.10.2 GABA Receptor Agonist Drug Product Introduction
      • 14.10.3 GlaxoSmithKline GABA Receptor Agonist Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.10.4 SWOT Analysis
    • 14.11 Eli Lilly and Company
    • 14.12 Elan Corporation
    • 14.13 Biocodex
    • 14.14 Athena Drug Delivery Solutions
    • 14.15 AstraZeneca
    • 14.16 Advicenne

    15 Conclusion

      16 Methodology

      Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global GABA Receptor Agonist Drug market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global GABA Receptor Agonist Drug market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

      Segmented by Category
      Bamaluzole
      Phenibut
      Baclofen
      Gaboxadol
      Klonopin (clonazepam)
      Tiagbine

      Segmented by End User/Segment
      Attention Deficit Hyperactivity Disorder (ADHD)
      Psychiatric Disorders and Depression
      Alzheimer
      Epilepsy and Seizure
      Anxiety and Sleep Disorders
      Obesity and Alcoholism

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      XenoPort
      VIVUS
      sanofi-aventis
      Pfizer
      OVATION Pharmaceuticals
      Osmotica Pharmaceutical
      Novartis
      NovaDel Pharma
      H.LundBeck, Merck and Co
      GlaxoSmithKline
      Eli Lilly and Company
      Elan Corporation
      Biocodex
      Athena Drug Delivery Solutions
      AstraZeneca
      Advicenne
      Buy now